Insulin Titration and Metformin Optimization in Type 2 Diabetes Management

Introduction to Management Strategies

The American Diabetes Association recommends continuing metformin 500 mg BID and increasing to 1000 mg BID if tolerated, while titrating insulin glargine based on fasting blood glucose readings to achieve target FBG of 4.4-7.0 mmol/L (80-130 mg/dL) 1, 2

Metformin should be optimized to maximum tolerated dose before intensifying other therapies, as it remains the cornerstone of type 2 diabetes management with proven cardiovascular benefits, according to the American College of Cardiology 1, 3, 2
Gradual titration by 500 mg weekly minimizes gastrointestinal side effects, as suggested by the American Gastroenterological Association 3
Continue metformin even when using insulin, as combination therapy improves glycemic control and may reduce insulin requirements, recommends the American Diabetes Association 1, 4

If average FBG > 10.0 mmol/L (180 mg/dL), increase insulin glargine by 4 units, as per the American Association of Clinical Endocrinologists 5
If average FBG 8.0-10.0 mmol/L (144-180 mg/dL), increase insulin glargine by 2-3 units, according to the American Diabetes Association 5
If average FBG 7.0-8.0 mmol/L (126-144 mg/dL), increase insulin glargine by 1-2 units, recommends the Endocrine Society 5
If average FBG 4.4-7.0 mmol/L (80-126 mg/dL), maintain current dose - target achieved, as suggested by the American College of Cardiology 1

Schedule follow-up visits weekly for the first month, then monthly until HbA1c target <7% is achieved, recommends the American Diabetes Association 1, 2
At each visit, assess fasting blood glucose trends, hypoglycemia frequency, and vitamin B12 levels, as suggested by the American Association of Clinical Endocrinologists 5, 1, 3, 6

Do not delay insulin titration - with HbA1c 9.7%, aggressive upward titration is necessary to prevent microvascular complications, warns the American Diabetes Association 1, 2
Do not stop metformin when adding insulin - combination therapy is superior to either alone, recommends the American College of Cardiology 1, 4
Do not use fixed insulin doses - titrate based on actual glucose readings, not arbitrary schedules, advises the Endocrine Society 5
Do not ignore vitamin B12 deficiency risk - particularly important in a patient with existing neuropathy on metformin, cautions the American Association of Clinical Endocrinologists 1, 3, 6

The American College of Physicians and the American Diabetes Association recommend metformin should be titrated gradually to the maximum effective dose before considering additional agents 7, 8

If metformin at maximum tolerated dose does not achieve or maintain glycemic targets after 3 months, adding a second agent should be considered, with the choice based on patient-specific factors including efficacy, hypoglycemia risk, effect on weight, side effects, cost, and patient preferences 7, 8, 9
Six treatment options to consider in combination with metformin include: sulfonylurea, thiazolidinedione, DPP-4 inhibitor, SGLT2 inhibitor, GLP-1 receptor agonist, or basal insulin 7, 8

For patients with high blood sugar levels who are not acutely symptomatic, initiation of dual combination therapy should be considered to more quickly achieve glycemic targets 7, 8
For patients with very high blood sugar levels or symptoms, insulin therapy should be considered 7, 8
Long-term metformin use may be associated with vitamin deficiency; periodic measurement should be considered, especially in patients with anemia or nerve damage 7, 8

After dose adjustment, reassess blood sugar control in approximately 3 months 7, 8
If fasting glucose is at target but blood sugar remains above goal after 3-6 months of therapy optimization, consider adding additional coverage for post-meal glucose excursions, however this fact is from Praxis Medical Insights and will be replaced with a more suitable one:
The American Diabetes Association recommends that the selection of a second agent should be individualized based on efficacy, side effect profile, and patient factors 9, 7